Pancreatic Ductal Adenocarcinoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Pancreatic Ductal Adenocarcinoma – Pipeline Review, H2 2016’, provides an overview of the Pancreatic Ductal Adenocarcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pancreatic Ductal Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Ductal Adenocarcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma

The report reviews pipeline therapeutics for Pancreatic Ductal Adenocarcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pancreatic Ductal Adenocarcinoma therapeutics and enlists all their major and minor projects

The report assesses Pancreatic Ductal Adenocarcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pancreatic Ductal Adenocarcinoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pancreatic Ductal Adenocarcinoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

BerGenBio AS

BioNTech AG

Celgene Corporation

Clovis Oncology, Inc.

COARE Biotechnology, Inc.

Concordia International Corp

Eli Lilly and Company

FibroGen, Inc.

Gilead Sciences, Inc.

Halozyme Therapeutics, Inc.

Immodulon Therapeutics Ltd.

Immunomedics, Inc.

Incuron, LLC

Incyte Corporation

Inflection Biosciences Limited

Inovio Pharmaceuticals, Inc.

InvivoGen Therapeutics

MedImmune, LLC

Medisyn Technologies, Inc.

Merck & Co., Inc.

Nerviano Medical Sciences S.r.l.

Novartis AG

OncoMed Pharmaceuticals, Inc.

Ono Pharmaceutical Co., Ltd.

Oryx GmbH & Co. KG

Pfizer Inc.

Quest PharmaTech Inc.

Sillajen Biotherapeutics

Soricimed Biopharma Inc.

Sun BioPharma, Inc.

Swedish Orphan Biovitrum AB

Tara Immuno-Oncology Therapeutics LLC

Tokai Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Pancreatic Ductal Adenocarcinoma Overview 6

Therapeutics Development 7

Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies 9

Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 11

Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance 12

Pancreatic Ductal Adenocarcinoma - Products under Development by Companies 15

Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes 18

Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development 19

Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment 52

Drug Profiles 65

Pancreatic Ductal Adenocarcinoma - Dormant Projects 234

Pancreatic Ductal Adenocarcinoma - Discontinued Products 235

Pancreatic Ductal Adenocarcinoma - Product Development Milestones 236

Appendix 243

List of Tables

List of Tables

Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2016 13

Number of Products under Development for Pancreatic Ductal Adenocarcinoma – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Development, H2 2016 20

Products under Development by Companies, H2 2016 21

Products under Development by Companies, H2 2016 (Contd..1) 22

Products under Development by Companies, H2 2016 (Contd..2) 23

Products under Investigation by Universities/Institutes, H2 2016 24

Pancreatic Ductal Adenocarcinoma – Pipeline by BerGenBio AS, H2 2016 25

Pancreatic Ductal Adenocarcinoma – Pipeline by BioNTech AG, H2 2016 26

Pancreatic Ductal Adenocarcinoma – Pipeline by Celgene Corporation, H2 2016 27

Pancreatic Ductal Adenocarcinoma – Pipeline by Clovis Oncology, Inc., H2 2016 28

Pancreatic Ductal Adenocarcinoma – Pipeline by COARE Biotechnology, Inc., H2 2016 29

Pancreatic Ductal Adenocarcinoma – Pipeline by Concordia International Corp, H2 2016 30

Pancreatic Ductal Adenocarcinoma – Pipeline by Eli Lilly and Company, H2 2016 31

Pancreatic Ductal Adenocarcinoma – Pipeline by FibroGen, Inc., H2 2016 32

Pancreatic Ductal Adenocarcinoma – Pipeline by Gilead Sciences, Inc., H2 2016 33

Pancreatic Ductal Adenocarcinoma – Pipeline by Halozyme Therapeutics, Inc., H2 2016 34

Pancreatic Ductal Adenocarcinoma – Pipeline by Immodulon Therapeutics Ltd., H2 2016 35

Pancreatic Ductal Adenocarcinoma – Pipeline by Immunomedics, Inc., H2 2016 36

Pancreatic Ductal Adenocarcinoma – Pipeline by Incuron, LLC, H2 2016 37

Pancreatic Ductal Adenocarcinoma – Pipeline by Incyte Corporation, H2 2016 38

Pancreatic Ductal Adenocarcinoma – Pipeline by Inflection Biosciences Limited, H2 2016 39

Pancreatic Ductal Adenocarcinoma – Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 40

Pancreatic Ductal Adenocarcinoma – Pipeline by InvivoGen Therapeutics, H2 2016 41

Pancreatic Ductal Adenocarcinoma – Pipeline by MedImmune, LLC, H2 2016 42

Pancreatic Ductal Adenocarcinoma – Pipeline by Medisyn Technologies, Inc., H2 2016 43

Pancreatic Ductal Adenocarcinoma – Pipeline by Merck & Co., Inc., H2 2016 44

Pancreatic Ductal Adenocarcinoma – Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 45

Pancreatic Ductal Adenocarcinoma – Pipeline by Novartis AG, H2 2016 46

Pancreatic Ductal Adenocarcinoma – Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 47

Pancreatic Ductal Adenocarcinoma – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 48

Pancreatic Ductal Adenocarcinoma – Pipeline by Oryx GmbH & Co. KG, H2 2016 49

Pancreatic Ductal Adenocarcinoma – Pipeline by Pfizer Inc., H2 2016 50

Pancreatic Ductal Adenocarcinoma – Pipeline by Quest PharmaTech Inc., H2 2016 51

Pancreatic Ductal Adenocarcinoma – Pipeline by Sillajen Biotherapeutics, H2 2016 52

Pancreatic Ductal Adenocarcinoma – Pipeline by Soricimed Biopharma Inc., H2 2016 53

Pancreatic Ductal Adenocarcinoma – Pipeline by Sun BioPharma, Inc., H2 2016 54

Pancreatic Ductal Adenocarcinoma – Pipeline by Swedish Orphan Biovitrum AB, H2 2016 55

Pancreatic Ductal Adenocarcinoma – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 56

Pancreatic Ductal Adenocarcinoma – Pipeline by Tokai Pharmaceuticals, Inc., H2 2016 57

Assessment by Monotherapy Products, H2 2016 58

Assessment by Combination Products, H2 2016 59

Number of Products by Stage and Target, H2 2016 61

Number of Products by Stage and Mechanism of Action, H2 2016 64

Number of Products by Stage and Route of Administration, H2 2016 68

Number of Products by Stage and Molecule Type, H2 2016 70

Pancreatic Ductal Adenocarcinoma – Dormant Projects, H2 2016 240

Pancreatic Ductal Adenocarcinoma – Discontinued Products, H2 2016 241

List of Figures

List of Figures

Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2016 13

Number of Products under Development for Pancreatic Ductal Adenocarcinoma – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Products, H2 2016 20

Assessment by Monotherapy Products, H2 2016 58

Number of Products by Top 10 Targets, H2 2016 60

Number of Products by Stage and Top 10 Targets, H2 2016 60

Number of Products by Top 10 Mechanism of Actions, H2 2016 63

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 63

Number of Products by Routes of Administration, H2 2016 67

Number of Products by Stage and Routes of Administration, H2 2016 67

Number of Products by Top 10 Molecule Types, H2 2016 69

Number of Products by Stage and Top 10 Molecule Types, H2 2016 69

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared